Combined PEX, Rituximab and Steroids in Acute IPF Exacerbations

Recruitment status:
Not recruiting
Primary Sponsor:
University of Pittsburgh
Recruitment countries:
United States
Health condition studied:
Link to the clinical trial website

About the trial

Drug: Combined Plasma Exchange (PEX), Rituximab, and Corticosteroids
Key inclusion and exclusion criteria:

  • Inclusion Criteria:

    - A diagnosis of idiopathic pulmonary fibrosis that fulfills American Thoracic Society
    Consensus Criteria.

    - Unexplained worsening or development of dyspnea or hypoxemia within 30 days leading
    to the current hospitalization.

    - Radiographic imaging showing ground-glass abnormality and/or consolidation
    superimposed on a background of reticular or honeycomb pattern consistent with UIP.

    - Intent on the part of the treating physician to use high dose steroid therapy as a
    therapeutic effort to treat a diagnosis of acute IPF exacerbation.

    Exclusion Criteria:

    - Diagnosis of documented infection based upon clinical evaluation and microbial

    - Diagnosis of thromboembolic disease by clinical assessment.

    - Diagnosis of an additional etiology for ALI/ARDS based upon clinical assessment to
    include sepsis, aspiration, trauma, inhalational injury, acute pancreatitis, drug
    toxicity, blood product transfusion reaction, or stem cell transplantation.

    - Diagnosis of congestive heart failure that accounts for the hypoxemia.

    - Presence of active hepatitis B infection.

    - Coagulopathy defined as an INR > 1.8, PTT > 2 x control, and platelet count < 50K.

    - Hyperosmolar state or diabetic ketoacidosis to suggest uncontrolled diabetes mellitus
    or uncontrolled hypertension (systolic BP > 160 mm Hg and diastolic BP > 100 mm Hg)
    which would contraindicated the use of corticosteroids.

    - Hemodynamic instability defined as a vasopressor requirement which would
    contraindicate the use of plasmapheresis.

    - History of reaction to blood products, murine-derived products, or prior exposures to
    human-murine chimeric antibodies,

    - History of malignancy.

    - Inability or unwillingness to accept a blood transfusion.

    - Inability or unwillingness to complete post- treatment surveillance for 60 days.

    - Diagnosis of major comorbidities expected to interfere with subjects study
    participation for 60 days.
  • Age minimum:  18 Years
  • Age maximum:  80 Years
  • Gender:  Both
Primary outcomes:
Feasibility and safety of the regimen in patients with IPF exacerbations
Secondary outcomes:
Survival to 60 days or survival to transplantation
Target sample size:
Study type:
Study design:
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
  • Name:   Michael Donahoe, MD
  • Address: 
  • Phone: 
  • Email: 
  • Affiliation:  University of Pittsburgh

Technical details

Scientific title:
Open-Label, Feasibility Study of Combined Plasma Exchange (PEX), Rituximab, and Corticosteroids in Patients With Acute Idiopathic Pulmonary Fibrosis Exacerbations
Sources of monetary support:
Please refer to primary and secondary sponsors
Secondary sponsors:
Main ID:
Secondary ID:
Date of registration:
Date of first enrollment:
March 2011
Last refreshed:
18 January 2016


Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record

Back to clinical trials list